Rocket Pharmaceuticals Company Insiders
| RCKT Stock | USD 3.25 0.01 0.31% |
Slightly above 70% of Rocket Pharmaceuticals' corporate insiders are selling. The analysis of the overall insider sentiment regarding Rocket Pharmaceuticals suggests that many insiders are alarmed. Rocket Pharmaceuticals employs about 299 people. The company is managed by 23 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 13.0 employees per reported executive.
| Jonathan Schwartz Executive Chief Medical Officer |
Insider Sentiment 30
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-10-14 | John Militello | Disposed 28918 @ 3.96 | View | ||
| 2025-08-27 | Elisabeth Bjork | Acquired 10000 @ 3.41 | View | ||
| 2025-08-19 | Martin Wilson | Disposed 588 @ 3 | View | ||
| 2025-08-18 | Martin Wilson | Disposed 1004 @ 3.06 | View | ||
| 2025-08-14 | Martin Wilson | Disposed 12109 @ 3.02 | View | ||
| 2025-07-03 | Aaron Ondrey | Disposed 1477 @ 2.88 | View | ||
| 2025-04-22 | John Militello | Disposed 718 @ 7.16 | View | ||
| 2025-04-10 | Gaurav Shah | Acquired 20000 @ 5.08 | View | ||
| 2025-04-09 | Kinnari Patel | Acquired 21099 @ 4.7 | View | ||
| 2025-04-04 | Aaron Ondrey | Disposed 7489 @ 5.29 | View |
Monitoring Rocket Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. Rocket Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Rocket Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Rocket will maintain a workforce of slightly above 300 employees by March 2026.Rocket Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4056) % which means that it has lost $0.4056 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7488) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2026. Return On Capital Employed is likely to drop to -0.68 in 2026. At this time, Rocket Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 28.6 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 314.9 M in 2026.Common Stock Shares Outstanding is likely to gain to about 114.5 M in 2026, despite the fact that Net Loss is likely to grow to (189.7 M). Rocket Pharmaceuticals owns a total of 108.22 Million outstanding shares. The majority of Rocket Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rocket Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rocket Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rocket Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2013-12-31 | Previous Quarter 111 M | Current Value 111.6 M | Avarage Shares Outstanding 46.3 M | Quarterly Volatility 35.7 M |
Rocket Pharmaceuticals Workforce Comparison
Rocket Pharmaceuticals is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,635. Rocket Pharmaceuticals retains roughly 299 in number of employees claiming about 18% of equities under Health Care industry.
Rocket Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Rocket Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.5 | 4 | 8 | 829,765 | 40,471 |
| 2025-09-01 | 0.7333 | 11 | 15 | 2,394,570 | 98,164 |
| 2025-06-01 | 1.1667 | 14 | 12 | 372,934 | 21,185 |
| 2025-03-01 | 2.1429 | 15 | 7 | 1,342,844 | 93,041 |
| 2024-12-01 | 0.1429 | 1 | 7 | 400,000 | 25,172 |
| 2024-09-01 | 0.7143 | 5 | 7 | 51,647 | 22,278 |
| 2024-06-01 | 1.1579 | 22 | 19 | 474,828 | 414,151 |
| 2024-03-01 | 0.6364 | 14 | 22 | 580,858 | 607,071 |
| 2023-12-01 | 0.75 | 6 | 8 | 42,115 | 46,155 |
| 2023-09-01 | 0.5 | 7 | 14 | 4,141,234 | 1,036,428 |
| 2023-06-01 | 2.7143 | 19 | 7 | 381,700 | 20,732 |
| 2023-03-01 | 3.875 | 31 | 8 | 2,305,049 | 222,548 |
| 2022-06-01 | 9.5 | 19 | 2 | 547,038 | 45,000 |
| 2022-03-01 | 2.5 | 15 | 6 | 896,465 | 135,562 |
| 2021-09-01 | 2.0 | 2 | 1 | 852,516 | 621,500 |
| 2021-06-01 | 1.8333 | 11 | 6 | 94,319 | 782,351 |
| 2021-03-01 | 0.6667 | 10 | 15 | 877,371 | 1,788,929 |
| 2020-12-01 | 1.0 | 5 | 5 | 347,720 | 106,761 |
| 2020-09-01 | 2.0 | 2 | 1 | 68,000 | 30,000 |
| 2020-03-01 | 2.0 | 12 | 6 | 1,062,231 | 707,904 |
| 2019-03-01 | 2.75 | 11 | 4 | 785,866 | 134,900 |
| 2018-12-01 | 1.5 | 6 | 4 | 1,338,280 | 162,125 |
| 2018-09-01 | 1.0 | 2 | 2 | 2.00 | 56,506 |
| 2018-03-01 | 1.1 | 11 | 10 | 890,300 | 1,095,634 |
| 2017-03-01 | 1.6667 | 5 | 3 | 755,000 | 3,266,066 |
| 2015-12-01 | 0.5 | 1 | 2 | 24,000 | 242,794 |
| 2015-09-01 | 2.0 | 2 | 1 | 33,857 | 9,857 |
| 2015-03-01 | 0.5526 | 21 | 38 | 16,075,976 | 40,455,800 |
Rocket Pharmaceuticals Notable Stakeholders
A Rocket Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rocket Pharmaceuticals often face trade-offs trying to please all of them. Rocket Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rocket Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John CPA | Senior VP | Profile | |
| CPA CPA | VP, Officer | Profile | |
| Mayo Pujols | Chief Officer | Profile | |
| Christopher Stevens | Chief Officer | Profile | |
| Martin JD | Secretary, Counsel | Profile | |
| Carlos Martin | Chief Officer | Profile | |
| Sarbani MBA | Chief Officer | Profile | |
| Jonathan Schwartz | Chief Medical Officer | Profile | |
| Aaron Ondrey | Chief Officer | Profile | |
| Isabel JD | Senior Officer | Profile | |
| PharmD MBA | Executive Officer | Profile | |
| Raj MBA | Senior Officer | Profile | |
| Sarbani Chaudhuri | Chief Officer | Profile | |
| Syed MD | Chief Officer | Profile | |
| LLM JD | Senior Affairs | Profile | |
| Gaurav MD | CEO Director | Profile | |
| M MBA | Bus Lead | Profile | |
| Jessie MBA | VP Fin | Profile | |
| Kevin Giordano | Director Communications | Profile | |
| MBA MBA | Pres COO | Profile | |
| Meg Dodge | Vice Communications | Profile | |
| Jonathan MD | Chief Development | Profile | |
| MD JD | Senior Officer | Profile |
About Rocket Pharmaceuticals Management Performance
The success or failure of an entity such as Rocket Pharmaceuticals often depends on how effective the management is. Rocket Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rocket management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rocket management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.64) | (0.67) |
Please note, the imprecision that can be found in Rocket Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rocket Pharmaceuticals. Check Rocket Pharmaceuticals' Beneish M Score to see the likelihood of Rocket Pharmaceuticals' management manipulating its earnings.
Rocket Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Rocket Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rocket Pharmaceuticals within its industry.Rocket Pharmaceuticals Manpower Efficiency
Return on Rocket Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 865.4K | |
| Net Loss Per Executive | 11.2M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 14.7M |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.